Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a post market, single-center, randomized, controlled, clinical study to assessTo evaluate the performance of self-administered Sentinox intranasal spray in preventing ARI caused by at least one respiratory virus
Epistemonikos ID: 1f99a0511e23a7b649d47bb149399b93b1188613
First added on: May 13, 2024